Equities Analysts Offer Predictions for Cartesian Therapeutics, Inc.’s Q1 2024 Earnings (NASDAQ:RNAC)

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) – Equities researchers at Leerink Partnrs issued their Q1 2024 EPS estimates for Cartesian Therapeutics in a research report issued on Tuesday, April 23rd. Leerink Partnrs analyst T. Smith expects that the company will post earnings of ($1.34) per share for the quarter. Leerink Partnrs currently has a “Outperform” rating on the stock. The consensus estimate for Cartesian Therapeutics’ current full-year earnings is ($3.21) per share. Leerink Partnrs also issued estimates for Cartesian Therapeutics’ Q2 2024 earnings at ($1.38) EPS, Q3 2024 earnings at ($1.27) EPS, Q4 2024 earnings at ($1.09) EPS, FY2024 earnings at ($5.03) EPS, FY2025 earnings at ($4.86) EPS and FY2026 earnings at ($5.58) EPS.

Cartesian Therapeutics (NASDAQ:RNAC) last posted its quarterly earnings results on Thursday, March 7th. The company reported ($2.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($2.10). The business had revenue of $8.27 million for the quarter. Cartesian Therapeutics had a negative return on equity of 58.21% and a negative net margin of 845.01%.

A number of other equities research analysts also recently weighed in on RNAC. Needham & Company LLC assumed coverage on shares of Cartesian Therapeutics in a research note on Tuesday, April 9th. They set a “buy” rating and a $42.00 price target for the company. HC Wainwright boosted their price target on shares of Cartesian Therapeutics from $2.00 to $54.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, SVB Leerink began coverage on shares of Cartesian Therapeutics in a research note on Tuesday. They issued an “outperform” rating and a $39.00 target price for the company.

Cartesian Therapeutics Stock Up 0.6 %

RNAC opened at $21.03 on Thursday. The business’s 50 day simple moving average is $19.20. Cartesian Therapeutics has a fifty-two week low of $11.66 and a fifty-two week high of $42.60.

Insider Buying and Selling at Cartesian Therapeutics

In other news, Director Timothy A. Springer bought 21,612 shares of the stock in a transaction on Thursday, March 14th. The stock was purchased at an average price of $16.20 per share, with a total value of $350,114.40. Following the completion of the purchase, the director now owns 1,017,228 shares of the company’s stock, valued at $16,479,093.60. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last 90 days, insiders bought 22,472 shares of company stock valued at $365,981. Corporate insiders own 31.20% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Cartesian Therapeutics stock. Hall Laurie J Trustee purchased a new stake in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 52,775 shares of the company’s stock, valued at approximately $34,000. Hall Laurie J Trustee owned 0.98% of Cartesian Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 86.95% of the company’s stock.

About Cartesian Therapeutics

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.